Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study to Determine the Safety and Efficacy of Onvansertib, A Novel, Oral, PLK1 Inhibitor in Patients With Proliferative Chronic Myelomonocytic Leukemia (CMML) and Myelodysplastic Syndrome/MPN Overlap Neoplasms Relapsed/Refractory or Intolerant to Available Therapies

NCT05549661 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05549661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05549661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study to Determine the Safety and Efficacy of Onvansertib, A Novel, Oral, PLK1 Inhibitor in Patients With Proliferative Chronic Myelomonocytic Leukemia (CMML) and Myelodysplastic Syndrome/MPN Overlap Neoplasms Relapsed/Refractory or Intolerant to Available Therapies
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Recruiting
Start date
April 4, 2023
Completion date
December 1, 2027
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic/myeloproliferative neoplasm, not otherwise specified, recurrent atypical chronic myeloid leukemia, recurrent chronic myelomonocytic leukemia, recurrent myelodysplastic/myeloproliferative neoplasm, refractory chronic myelomonocytic leukemia, refractory myelodysplastic/myeloproliferative neoplasm